The Role of Hepcidin on Iron and Ferritin Levels in Hemodialysis Patients
Authors
-
Hamed Naghdbishi
Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran
https://orcid.org/0009-0008-3349-818X
-
Monire Amerian
Department of Nephrology, Imam Hossain Center for Education, Research and Treatment, Shahroud University of Medical Sciences, Shahroud, Iran.
https://orcid.org/0000-0002-2175-4720
-
Hoofar Rafiee
Department of Nephrology, Imam Hossain Center for Education, Research and Treatment, Shahroud University of Medical Sciences, Shahroud, Iran.
https://orcid.org/0000-0003-1365-4081
-
Elnaz Sarkheyl
Department of Internal medicine, Imam Hossain Center for Education, Research and Treatment, Shahroud University of Medical Sciences, Shahroud, Iran.
https://orcid.org/0000-0001-5740-2092
-
Maryam Abbaszadeh
Department of Emergency medicine, Imam Hossain Center for Education, Research and Treatment, Shahroud University of Medical Sciences, Shahroud, Iran.
https://orcid.org/0000-0003-0450-855X
-
Mohammad Bagher Sohrabi
School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
https://orcid.org/0000-0001-6768-832X
DOI:
https://doi.org/10.22100/ijhs.v11i4.1216Keywords:
Hemodialysis, Hepcidin, Serum iron, FerritinAbstract
Background: Anemia is a common complication in dialysis patients, the most important of which are decreased erythropoietin, iron deficiency, blood loss, dialysis, and chronic inflammation. Hepcidin plays a key role in iron homeostasis in dialysis patients and acts as a natural regulator of hemostasis. Given the importance of the subject and the high frequency of iron homeostasis disorders in hemodialysis patients, as well as the lack of sufficient documentation in this regard, the present study aimed to the role of hepcidin on iron and ferritin levels in hemodialysis patients in Shahroud city in 2024.
Methods: This study was a descriptive-analytical study that was conducted cross-sectionally on hemodialysis patients in Shahroud city at Imam Hossein Hospital during 2024. In this plan, after initial measures and obtaining written and informed consent, eligible patients were asked to stop taking iron compounds two weeks before the study and not to use any iron supplements without coordination with the administrators. For all patients, iron factors and ferritin were measured using standard laboratory methods, and then hepcidin was measured using ELISA.
Results: In the present study, out of 85 patients studied, 45 (52.9%) were male and 40 (47.1%) were female. The mean age of the patients was 54.31±12.59 years (28-79 years). The mean hepcidin level was 60.39±4.22 mg/dL. It was also found that the level of hepcidin was significantly associated with the duration of dialysis (P-value=0.001) and the number of dialysis sessions per week (P-value=0.006) and had no significant relationship with other variables.
Conclusion: The results of this study showed that there was a significant relationship between hepcidin levels, dialysis duration, and the number of dialysis sessions per week. It is necessary to control iron levels before starting hemodialysis, and to adjust the dialysis program for each patient specifically.
References
Ueda N, akasawa K. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease. Nutrients 2018; 10(9): 1173. doi: 10.3390/nu10091173
Valenti L, Girelli D, Valenti GF, Castagna A, Como G, Campostrini N, et al. HFE Mutations Modulate the Effect of Iron on Serum Hepcidin-25 in Chronic Hemodialysis Patients. Clin J Am Soc Nephrol 2009; 4(8): 1331-1337. doi: 10.2215/CJN.01370209
Sheetz M, Barrington P, Callies S, Berg PH, McColm J, Marbury T, et al. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br J Clin Pharmacol 2019; 85(5): 935-948. doi: 10.1111/bcp.13877
Chenini S, Delaby C, Rassu AL, Barateau L, Vialaret J, Hirtz C, et al. Hepcidin and ferritin levels in restless legs syndrome: a case-control study. Sci Rep 2020; 10: 11914. doi: 10.1038/s41598-020-68851-0
Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, et al. Reduction of Serum Hepcidin by Hemodialysis in Pediatric and Adult Patients. Clin J Am Soc Nephrol 2010; 5(6): 1010-1014. doi: 10.2215/CJN.08161109
Nunes LL, Dos Reis LM, Osorio R, Guapyassú HK, Moysés RM, Filho HL, et al. High ferritin is associated with liver and bone marrow iron accumulation: Effects of 1-year deferoxamine treatment in hemodialysis-associated iron overload. PLoS One 2024; 19(8): e0306255. doi: 10.1371/journal.pone.0306255
Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al. Hepcidin-A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease. Clin J Am Soc Nephrol 2009; 4(6): 1051-1056. doi: 10.2215/CJN.05931108
Leaf DE, Rajapurkar M, Lele SS, Mukhopadhyay B, Boerger EA, Mc Causland FR, et al. Iron, Hepcidin, and Death in Human AKI. J Am Soc Nephrol 2019; 30(3): 493-504. doi: 10.1681/ASN.2018100979
Van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, et al. Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents. PLoS One 2012; 7(7): e39783. doi: 10.1371/journal.pone.0039783
Ganz T, Jung G, Naeim A, Ginzburg Y, Pakbaz Z, Walter PB, et al. Immunoassay for human serum erythroferrone. Blood 2017; 130:1243-6. doi: 10.1182/blood-2017-04-777987
Nicolas G1, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002; 99:4596-01. doi: 10.1073/pnas.072632499
Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110:1037-44. doi: 10.1172/JCI0215686
Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117:1926-32. doi: 10.1172/JCI31370
Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010; 95:505-8. doi: 10.3324/haematol.2009.013136
Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009; 75:976-81. doi: 10.1038/ki.2009.21
Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, et al. Salusky. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients Clin J Am Soc Nephrol 2010; 5:1010-4. doi: 10.2215/CJN.08161109
Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 2009; 39:883-90. doi: 10.1111/j.1365-2362.2009.02182.x
Kuragano T, Shimonaka Y, Kida A, Furuta M, Nanami M, Otaki Y, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol 2010; 31:534-40. doi: 10.1159/000312381
Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A. Association of Prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 2008; 28:115-121. doi: 10.1159/000109968
van der Putten K, Jie KE, van den Broek D, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail 2010; 12:943-50. doi: 10.1093/eurjhf/hfq099
Ghahramanfard F, Yarmohamadi M, Ghorbani R, Semnani V, Mirzaei A, Ghushchian Chubmasgedi M. Hepcidin in hemodialysis patients and its association with anemia and serum iron indices. Renal Inj Prev 2019; 8(2): 146-150. doi: 10.15171/jrip.2019.27
Bonomini M, Masola V, Procino G, Zammit V, Divino-Filho JC, Arduini A, et al. How to Improve the Biocompatibility of Peritoneal Dialysis Solutions (without jeopardizing the Patient's Health). Int J Mol Sci 2021; 22(15): 7955. doi: 10.3390/ijms22157955
Poles J, Karhu E, McGill M, McDaniel HR, Lewis JE. The effects of twenty-four nutrients and phytonutrients on immune system function and inflammation: A narrative review. J Clin Transl Res 2021; 7(3): 333-376.
Bello AK, Okpechi IG, Osman MA, Cho Y, Htay H, Jha V, et al. Epidemiology of haemodialysis outcomes. Nat Rev Nephrol 2022; 18(6): 378-395. doi: 10.1038/s41581-022-00542-7
Rosansky SJ, Eggers P, Jackson K, Richard Glassock R, Clark, WF. Early Start of Hemodialysis May Be Harmful. Arch Intern Med 2011; 171(5):396-403. doi: 10.1001/archinternmed.2010.415
Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010; 363(7):609-19. doi: 10.1056/NEJMoa1000552
Malyszko J, Mysliwiec M. Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res 2007; 30(1):15-30. doi: 10.1159/000098522
Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 2011; 80(3):240-4. doi: 10.1038/ki.2011.141
Published
Issue
Section
License
The Copyright Form should be downloaded and signed by corresponding author in the fourth step "upload supplementary files" during submission process.
After acceptance, copyright form should be downloaded and signed by all authors one by one ( "summery --> supp. file" part and click on "add a supplementary file" link).
